Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure

• Status: Not yet recruiting
• Trial end date: 2026-06-30

Summary

Schizophrenia, bipolar and major depressive disorders collectively affect over 10 million people across the EU and are associated with annual healthcare and societal costs in excess of 100 billion Euros. When diagnosed with one of these disorders, patients are prescribed psychotropic medication such as antidepressants, mood stabilisers or antipsychotics. It is unknown whether this first-line treatment will be successful. After this first-line treatment fails, usually a second-line treatment is initiated, and when this is not successful either a third-line treatment is initiated. Third-line treatments are quite successful, especially when compared to second-line treatments. The research question is whether the third-line treatments (early-intensified treatments) would be more efficacious than the current second-line treatments (treatment as usual) for schizophrenia, bipolar and major depressive disorders. If this is indeed the case, this could lead to the prevention of unnecessary trials of ineffective treatments and adaptations of worldwide guidelines as well as a reduction of healthcare and societal costs.

• Phase: Phase 4

Details

• Lead Sponsor: Dr. Inge Winter
• Collaborator: Westfälische Wilhelms-Universität Münster
• Treatments: Antidepressive Agents; Antipsychotic Agents; Citalopram; Clozapine; Duloxetine Hydrochloride; Esketamine; Lamotrigine; Quetiapine Fumarate; Sertraline; Valproic Acid; Venlafaxine Hydrochloride